Dogwood Therapeutics Inc DWTX 深 沪
等待开盘 02-06 09:30:00 美东时间
3.17
+0.090
+2.92%
华盛通- 最 高3.285
- 今 开3.02
- 成交量 6.10万股
- 最 低 3.0006
- 昨 收 3.08
- 总市值 726.94万
- 52周最高 14.69
- 市盈率 静 --
- 换手率 2.66%
- 52周最低 2.60
- 委 比 -60.26%
- 总股本 229.32万
- 历史最高 417.75
- 量 比 1.41
- 振 幅 9.23%
- 历史最低 1.87
- 每 手 1
- 风险率 1.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 苹果、SanDisk、西部数据、卡特彼勒、德克斯户外、霍尼韦尔、西南航空、万事达等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Praxis Precision Medicine"买入"评级，目标价从340美元升至1245美元；HC Wainwright & Co.：维持Perspective Therapeutics"买入"评级，目标价从10美元升至12美元
02-02 14:15
HC Wainwright & Co. Reiterates Buy on Dogwood Therapeutics, Maintains $12 Price Target
HC Wainwright & Co. analyst Sean Lee reiterates Dogwood Therapeutics (NASDAQ:DWTX) with a Buy and maintains $12 price target.
01-30 19:26
Dogwood Therapeutics Highlights Pipeline Expansion And Clinical Progress Toward Non-Opioid Cancer Pain And Neuropathy Treatments; Key Halneuron And SP16 Milestones Targeted For 2026
Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("DWTX" or "Company"), a company that focuses on developing new non-opioid medicines to treat pain and neuropathy, issues a corporate update in the following Letter to
01-20 21:37
What's Driving the Market Sentiment Around Dogwood Therapeutics Inc?
Dogwood Therapeutics Inc's (NYSE:DWTX) short interest as a percent of float has...
2025-12-25 00:00
Dogwood Therapeutics Reports Interim Results For Halneuron In Chemotherapy-Induced Neuropathic Pain Study; Expects Top-Line Results Availability In Q3 2026
- Halneuron® treated patients separating from placebo on pain improvement assessment; Company expects top-line results availability in Q3 2026 -- The overall study dropout rate of ~4.4% is far below rates typically
2025-12-22 23:17
Dogwood Therapeutics Files For New Intellectual Property Protection For Synthetic Halneuron
Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has filed for new intellectual property
2025-12-02 21:04
Dogwood Therapeutics Launches $8.56M At-The-Market Stock Offering Under New Equity Distribution Agreement
On November 28, 2025, Dogwood Therapeutics, Inc., a Delaware corporation (the "Company"), entered into an Equity Distribution Agreement (the "Agreement") with Northland Securities, Inc. (trade
2025-11-29 03:52
Dogwood Therapeutics Enrolls First 100 Patients In Ongoing HALT-CINP Phase 2b CINP Trial
- Continued low early termination rate among the first 80 study completers suggests Halneuron® and placebotreatmenthave been well toleratedATLANTA, GEORGIA / ACCESS Newswire / November 11, 2025 / Dogwood
2025-11-11 21:47
Dogwood Therapeutics Q3 EPS $(8.20) Misses $(1.58) Estimate
Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(8.20) per share which missed the analyst consensus estimate of $(1.58) by 418 percent. This is a 300 percent decrease over losses of $(2.05) per share
2025-11-06 21:50
Dogwood Therapeutics Announces Business Combination Plans
Dogwood Therapeutics ( ($DWTX) ) has provided an announcement. On October 9, 20...
2025-10-10 04:55
